Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension

In this small cohort of patients with moderate to severe pulmonary hypertension in the setting of POPH, we have shown that ambrisentan monotherapy can significantly improve pulmonary hemodynamic responses without adverse effect on hepatic function.